<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03868111</url>
  </required_header>
  <id_info>
    <org_study_id>2019-02-001</org_study_id>
    <nct_id>NCT03868111</nct_id>
  </id_info>
  <brief_title>Sufentanil as Adjuvant of Balanced Anesthesia</brief_title>
  <official_title>Comparison Between Sufentanil and Remifentanil as General Anesthetic Adjuvant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kangbuk Samsung Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to compare the efficacy and safety between sufentanil and
      remifentanil as an adjuvant of balanced general anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesized that sufentanil would reduce postoperative pain than
      remifentanil without prolonging recovery times in minor laparoscopic surgery when
      administered equivalent antinociceptive doses during surgery. Intraoperative opioid
      administration for equivalent nociception-antinociception balance could be achieved via
      surgical pleth index (SPI)-guided analgesia. This study was designed to compare the efficacy
      and safety between sufentanil and remifentanil as an adjuvant of balanced anesthesia in
      patients undergoing laparoscopic cholecystectomy under SPI-guided opioid administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Actual">January 12, 2020</completion_date>
  <primary_completion_date type="Actual">January 12, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative wound pain score</measure>
    <time_frame>10 minutes after surgery</time_frame>
    <description>The pain score is evaluated by 10 point visual analogue scale at post-anesthesia care unit. The visual analogue scale is presented as a 10-cm line with verbal descriptors indicating &quot;no pain&quot; and &quot;pain as bad as it could be&quot;. The visual analogue scale ranges from 0 to 10, representing minimum and maximum pain levels, respectively.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Sufentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Balanced anesthesia is maintained with 1 MAC desflurane and sufentanil during laparoscopic cholecystectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remifentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Balanced anesthesia is maintained with 1 MAC desflurane and remifentanil during laparoscopic cholecystectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>The infusion rate of sufentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.</description>
    <arm_group_label>Sufentanil</arm_group_label>
    <other_name>Group S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>The infusion rate of remifentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.</description>
    <arm_group_label>Remifentanil</arm_group_label>
    <other_name>Group R</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged between 19 and 65 years

          -  Patients with American Society of Anesthesiologists physical status I or II

          -  Patients scheduled for elective laparoscopic cholecystectomy under balanced general
             anesthesia for benign cholecystic diseases

          -  Patients obtaining written informed consent

        Exclusion Criteria:

          -  Patients with asthma or hypertension

          -  Patients with an inability to express their pain accurately

          -  Patients with an inability to understand the pain scale

          -  Patients with chronic abdominal pain or chronic pain syndrome

          -  Patients who required to convert to laparotomy from laparoscopic surgery

          -  Patients who required to receive incidental lower abdominal procedures owing to
             adhesion, injury, or other incidental findings at the lower abdominal cavity

          -  Patients with a history of drug or alcohol abuse

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoung-Ho Ryu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kangbuk Samsung Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03181</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2019</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kangbuk Samsung Hospital</investigator_affiliation>
    <investigator_full_name>Kyoung-Ho Ryu, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

